Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05660967 · ClinicalTrials.gov registry record · Phase 2
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
A Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by Genmab.
- Active
- Registry status
- Phase 2
- Development phase
- 111
- Enrollment target
- 20
- Study locations
NCT05660967: Active Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by Genmab.
NCT05660967 is a Phase 2 study of Diffuse Large B Cell Lymphoma that is active but no longer recruiting, run by Genmab. The registered enrollment target is 111 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05660967, a Phase 2 study of Diffuse Large B Cell Lymphoma, is active but no longer recruiting, sponsored by Genmab.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 111 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.
Primary Outcome
Percentage of participants achieving CR. Assessed by the Investigator per Lugano criteria
Conditions Studied
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Epcoritamab
Study Locations (20)
Other
- Kepler Universitätsklinikum - Linz
- LKH - Universitätsklinikum der PMU Salzburg - Salzburg
- Klinikum Wels-Grieskirchen GmbH - Wels
- Institut Jules Bordet - Anderlecht
- ZNA - Antwerp
- UZ Brussels - Jette
- UZ Leuven - Leuven
- AZ Delta - Roeselare
- Vitaz - Temse
- AZ Turnhout - Campus Sint-Elisabeth - Turnhout
- Fakultni nemocnice Hradec Kralove - Hradec Králové
- Fakultni nemocnice v Motole - Prague
- Vseobecna fakultni nemocnice v Praze - Prague
- CHU Angers - Hôpital Hôtel Dieu - Angers
- Hôpital Henri Mondor - Créteil
- Hopital Claude Huriez - CHRU Lille - Lille
- Hopital de la Conception - APHM - Marseille
- CHU de Nantes - Hotel Dieu - Nantes
- Hôpital Saint-Antoine - Paris
Wisconsin
- UW Cancer Center at ProHealth Care - Waukesha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2026-06-28 |
| Phase | Phase 2 |
What the registry record for NCT05660967 still lists
NCT05660967 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (49% lower).
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Lenalidomide is the first listed.
NCT05660967 names 20 study sites across 2 states, led by Other, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05660967 about?
NCT05660967 is a clinical study titled "Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma". The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an ...
What is the current status of trial NCT05660967?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2023-03-06. Estimated completion is 2026-06-28.
What conditions does trial NCT05660967 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT05660967?
The interventions under investigation include: Lenalidomide (DRUG), Epcoritamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05660967?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05660967 being conducted?
This trial has 20 study locations across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05660967's enrollment target sits among peer trials
111 40th of 114 higher than 75 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
RECRUITING · Phase 2
-
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI